二代结肠胶囊内镜对进展期肿瘤的诊断准确性
本研究纳入意大利和西班牙4个人群筛查项目中粪便免疫化学试验(FIT)阳性的50-69岁受试者,评估二代结肠胶囊内镜(CCE-2)以传统结肠镜(TC)为金标准对进展期肿瘤(AN)的诊断准确性。178例完成两者,TC检出59例AN;以6 mm为转诊阈值时CCE-2敏感性90%、特异性66.1%,以10 mm为阈值时分别为76.7%和90.7%。
要点
- FIT阳性筛查人群中,CCE-2以6 mm为阈值检出AN的敏感性达90%。
- 6 mm阈值下CCE-2特异性66.1%,假阳性多因检出非进展期腺瘤。
- 10 mm阈值下CCE-2特异性升至90.7%,但敏感性降至76.7%。
核心结论
- 在疾病富集人群中,CCE-2以6 mm为阈值诊断AN具有高敏感性。
- CCE-2特异性看似较低与选择AN作为主要结局有关。
研究设计与样本
- 前瞻性诊断准确性研究,纳入意大利和西班牙4个人群筛查项目中FIT阳性的50-69岁受试者。
- CCE-2视频由对传统结肠镜结果不知情的内镜医师判读。
主要发现
- 传统结肠镜共检出59例进展期肿瘤(AN)。
- 6 mm阈值下CCE-2诊断AN的敏感性90%、特异性66.1%、PPV 57.4%、NPV 92.9%,结肠镜转诊率52.8%。
- 10 mm阈值下CCE-2诊断AN的敏感性76.7%、特异性90.7%、PPV 80.7%、NPV 88.4%,结肠镜转诊率32%。
- CCE-2检出9例已发生的结直肠癌中的8例。
- 6 mm阈值下41例假阳性中34例(82.9%)传统结肠镜示非进展期腺瘤。
关键数值与推荐
- CCE-2以6 mm为结肠镜转诊阈值时,诊断AN的敏感性为90%、特异性为66.1%。
- CCE-2以10 mm为结肠镜转诊阈值时,诊断AN的敏感性为76.7%、特异性为90.7%。
临床怎么用
- 在FIT阳性筛查人群中,可考虑CCE-2作为结肠镜检查前的无创分诊工具。
- 选用6 mm阈值可提高AN检出敏感性但增加结肠镜转诊率。
- 选用10 mm阈值可降低转诊率但可能漏诊部分AN。
局限性
- 研究在疾病富集人群中进行,结论外推至一般筛查人群需谨慎。
- 完成CCE-2和传统结肠镜的受试者仅178例(87.7%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Second-generation colon capsule endoscopy (CCE-2) has shown promising accuracy for the diagnosis of overall neoplasia. Advanced neoplasia (AN) represents the main target of colorectal cancer screening programs. Our aim was to assess the diagnostic accuracy of CCE-2 for the detection of AN in patients with a positive result for the fecal immunochemical test (FIT) who are undergoing screening. METHODS: Patients aged 50 to 69 years with a positive result for the FIT in 4 population screening programs in Italy and Spain were enrolled. Screenees were asked to undergo CCE-2, followed by traditional colonoscopy (TC). TC was performed the same day or the following morning. Bowel preparation included a split-dose polyethylene glycol-based regimen, with sodium phosphate (NaP) with gastrografin as boosters. The CCE-2 video was read by an endoscopist blinded to the results of TC. The main outcomes were CCE-2 accuracy in terms of sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for AN when using 2 different size thresholds for TC referral (ie, polyps ≥6 mm and ≥10 mm). RESULTS: Two hundred twenty-two patients were enrolled, and 178 patients completed both CCE-2 and TC (87.7%). Overall, 59 cases of AN were detected at TC. CCE-2 sensitivity was 90%, specificity was 66.1%, PPV was 57.4%, and NPV was 92.9% for AN when using a 6-mm cut-off (TC referral rate, 52.8%) and 76.7%, 90.7%, 80.7%, and 88.4% when using a 10-mm cut-off (TC referral rate, 32%), respectively. CCE-2 detected that 8 of 9 already developed colorectal cancers. Among the 41 false positives at the 6-mm cut-off, 34 (82.9%) presented with a nonadvanced adenoma at TC. Mean transit time was 4 hours and 4 minutes, and ≥70% of patients excreted the capsule within 5 hours. CONCLUSIONS: In an enriched disease setting, we showed the high sensitivity of CCE-2 for the diagnosis of AN at a 6-mm cut-off. The apparently low CCE-2 specificity is related to the choice of AN as the main outcome. (Clinical trial registration number: ISRCTN 62158762.).
引用
- Pecere S, Senore C, Hassan C, et al. Accuracy of colon capsule endoscopy for advanced neoplasia. Gastrointest Endosc. 2019. PMID: 31629719. doi:10.1016/j.gie.2019.09.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。